Table 10.
Caffeine (+)-catechin and theobromine: therapeutic perspectives in COVID-19
| Caffeine | (+)-Catechin | Theobromine | ||
|---|---|---|---|---|
| Cytokines storm inhibition | ||||
| Interleukin 8 antagonist | P.a | 0.213 | – | 0.359 |
| P.i | 0.009 | – | 0.005 | |
| Interleukin 1 antagonist | P.a | 0.168 | – | 0.126 |
| P.i | 0.050 | – | 0.083 | |
| Interleukin 4 antagonist | P.a | – | 0.222 | – |
| P.i | – | 0.016 | – | |
| Interleukin 10 antagonist | P.a | – | 0.161 | – |
| P.i | – | 0.013 | – | |
| Interleukin 6 antagonist | P.a | – | 0.208 | – |
| P.i | – | 0.072 | – | |
| Interferon gamma antagonist | P.a | – | 0.138 | – |
| P.i | – | 0.056 | – | |
| Interleukin 5 antagonist | P.a | – | – | 0.106 |
| P.i | – | – | 0.036 | |
| Tumour necrosis factor antagonist | P.a | 0.309 | – | 0.241 |
| P.i | 0.015 | – | 0.027 | |
| Tumour necrosis factor alpha antagonist | P.a | 0.227 | – | 0.181 |
| P.i | 0.019 | – | 0.032 | |
| Respiratory analeptic | P.a | 0.906 | 0.403 | 0.700 |
| P.i | 0.004 | 0.067 | 0.015 | |
| Antitussive | P.a | 0.453 | 0.524 | 0.347 |
| P.i | 0.014 | 0.009 | 0.027 | |
| Bronchodilator | P.a | 0.379 | 0.143 | 0.286 |
| P.i | 0.006 | 0.045 | 0.011 | |
| Vasoprotector | P.a | 0.391 | 0.652 | 0.309 |
| P.i | 0.082 | 0.014 | 0.147 | |
| Thromboxane B2 antagonist | P.a | 0.395 | 0.459 | 0.378 |
| P.i | 0.106 | 0.054 | 0.122 | |
| Gastrointestinal disorders treatment | P.a | 0.271 | – | 0.166 |
| P.i | 0.006 | – | 0.068 | |
| Prostaglandin-A1 DELTA-isomerase inhibitor | P.a | 0.274 | 0.217 | 0.209 |
| P.i | 0.109 | 0.166 | 0.177 | |
| Antihistaminic | P.a | 0.153 | – | – |
| P.i | 0.065 | – | – | |
| Heat shock protein 90 antagonist | P.a | 0.101 | 0.107 | – |
| P.i | 0.042 | 0.038 | – | |
| MAP kinase kinase 4 inhibitor | P.a | 0.214 | 0.377 | 0.228 |
| P.i | 0.163 | 0.008 | 0.137 | |
| Antinociceptive | P.a | 0.238 | 0.447 | 0.237 |
| P.i | 0.235 | 0.073 | 0.236 | |